Ginkgo Bioworks

On 16 December 2020, it was reported that Ginkgo Bioworks would acquire the primary assets of Novogy's Microbial Engineering Platform. On 11 May 2021, Gingko Bioworks announced plans of going public through a merger with SPAC Soaring Eagle at a $17.5 billion valuation.On 14 May 2021, Ginkgo announced its new ticker for the NYSE will be DNA. The ticker was previously used by Genentech, who stopped using the ticker after they were acquired by Roche. Trading began on September 17, 2021. The investment management firm Baillie Gifford became the largest shareholder with the purchase of 167.75 million shares on 31 March 2022.On 14 March 2022, it was reported that Ginkgo Bioworks signed a Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform. On 6 June 2022, it was reported that Ginkgo Bioworks has acquired assets from Bitome, an Integrated Metabolite Monitoring Platform. On 25 July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal.On 27 July 2022, it was reported that Ginkgo Bioworks would acquire Bayer's Biologics Research & Development site, located in West Sacramento. Ginko will enter into a new multi-year platform collaboration with Bayer. The deal includes the integration of the R&D platform assets from Joyn Bio, a joint-venture between Leaps by Bayer investments and Ginkgo Bioworks. On 4 October 2022, it was reported that Ginkgo Bioworks would acquire France-based adaptive laboratory evolution instruments developer Altar and California-based Circularis to strengthen capabilities in cell and gene therapy.In October 2022, Bloomberg News reported that Ginkgo Bioworks partnered with Intelligence Advanced Research Projects Activity to create a software tool to help detect when biological organisms have been genetically engineered. The tool known as ENDAR could be used to provide an early warning of bioweapons and other man-made biological threats.